MedicalLogic   Report issue

For profit Phase 2
Founded: Seoul Korea, Republic of (2015)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

erlotinib (tarceva) (1 trial)

phytosome (1 trial)

Silibinin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3